Pfizer Poised for 20% Upside with Strong Growth Prospects

Pfizer (PFE) is positioned for a potential 20% upside, according to analysts at 24/7 Wall St., who set a price target of $33.18 for the stock. Currently trading at $27.60, Pfizer offers a 6% dividend yield and a forward earnings multiple of 10x, making it a compelling value play compared to peers like Merck (MRK) at 15x and Bristol Myers Squibb (BMY) at 9x.

The company's growth prospects are fueled by its Metsera GLP-1 deal, targeting the $150 billion obesity market. Phase 2b data showed a 12% weight loss, with a first approval anticipated for 2028. Additionally, Pfizer's oncology pipeline and cost-saving programs aim to drive further growth, with management projecting $9.7 billion in savings through 2029.

Pfizer has consistently beaten earnings estimates for the past ten quarters, with second-quarter revenue reaching $15 billion and adjusted EPS of 77 cents. The stock has gained 16.6% year-to-date but has slipped 3.33% over the past month. Analysts remain cautious, with 16 Hold ratings versus 10 Buy ratings, citing risks such as generic competition and pricing discounts.

Despite these challenges, 24/7 Wall St. maintains a Buy rating with high confidence, citing Pfizer's strong valuation and dividend income. The bull case projects the stock reaching $37 if the obesity and oncology pipelines deliver as expected, while the bear case sees it stuck near $29.32 due to external pressures.